Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL VALERATE AND DIENOGEST versus STILPHOSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL VALERATE AND DIENOGEST versus STILPHOSTROL.
ESTRADIOL VALERATE AND DIENOGEST vs STILPHOSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol valerate is a prodrug of estradiol, an estrogen that binds to estrogen receptors (ERα and ERβ) to regulate gene transcription, promoting endometrial growth and suppressing gonadotropins. Dienogest is a progestin with partial antiandrogenic activity, binding to progesterone receptors to inhibit endometrial proliferation and ovulation, and reducing androgen synthesis.
Synthetic nonsteroidal estrogen; binds to estrogen receptors, inducing tumor regression in hormone-sensitive cancers.
One tablet (2 mg estradiol valerate and 3 mg dienogest) once daily orally, without interruption, following the first day of menstrual cycle.
0.5-1 mg/kg intravenously daily for 5 days, then 0.5 mg/kg intramuscularly weekly.
None Documented
None Documented
Estradiol valerate: Terminal half-life of estradiol is 13-15 hours; valerate ester is rapidly hydrolyzed, so systemic estradiol half-life applies. Dienogest: Terminal half-life ~8-10 hours, increasing to ~12-14 hours with multiple dosing due to competitive inhibition of CYP3A4.
Terminal elimination half-life: 50-60 hours (range 40-80 hr) due to enterohepatic recirculation; clinical context: steady-state achieved in ~10-14 days
Estradiol valerate: Renal (primarily as glucuronide and sulfate conjugates) ~40%, Fecal ~60%. Dienogest: Renal ~60% (mostly unchanged), Fecal ~30%.
Renal (primarily as glucuronide conjugates, 70-80%); fecal (biliary excretion of conjugates, 20-30%); <5% unchanged
Category D/X
Category C
Estrogen
Estrogen